Regulatory Strategy for a New Active Substance (NAS): Global Clinical Development Masterclass
Venue: Inter City Hotel, Katharina-Paulus-Straße 5, 10557 Berlin, Germany
Start: Tuesday 19 Nov 2024 12:30
End: Thursday 21 Nov 2024 15:00
This is event is brought to you by TOPRA
The Regulatory Strategy for a New Active Substance (NAS): Global Clinical Development Masterclass will help you to develop regulatory strategies for all aspects of global clinical research.
Featuring expert speakers from industry-leading organisations including AstraZeneca, Boyds, CROS-NT, Gilead, Highbury Regulatory Science, Janssen Infectious Diseases, Lundbeck, Trilogy Writing & Consulting and Worldwide Clinical Trials, it will also enable you to address practical regulatory issues in this area.
Join us on 19-21 November 2024, either in-person in Berlin or online, and you will:
- Gain a thorough understanding of regulations and international directives related to clinical development of new medicines
- Be able to critically assess clinical programme strategies used in the development and registration of new medicines, and provide effective regulatory leadership
- Understand EU legislation on clinical development, and the procedures for clinical trial reports, overviews, and summaries for optimal product labelling
- Develop a network to support you for the rest of your career
- Earn 19 CPD hours
This course is part of our range of masterclasses and is Module 4 in our MSc programme. Our masterclasses are developed and delivered by a faculty of expert speakers and validated by the University of Hertfordshire.
Discounted rates are available for TOPRA MSc students, those working for regulatory or government agencies, academic institutions, charities, patient groups, or in full time education.